Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martijn Kedde

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Cell Cycle (Georgetown, Tex.)|April 17, 2008
Interplay between microRNAs and RNA-binding proteins determines developmental processesMartijn Kedde, Reuven Agami
Nature Reviews. Cancer|August 9, 2011
MicroRNA regulation by RNA-binding proteins and its implications for cancerMarieke van Kouwenhove, Martijn Kedde, Reuven Agami
RNA (New York, N.Y.)|March 28, 2008
miR-148 targets human DNMT3b protein coding regionAnja M Duursma, Martijn Kedde, Mariette Schrier, et al.
Nature Cell Biology|September 7, 2010
A Pumilio-induced RNA structure switch in p27-3' UTR controls miR-221 and miR-222 accessibilityMartijn Kedde, Marieke van Kouwenhove, Wilbert Zwart, et al.
The Journal of Biological Chemistry|November 14, 2006
Telomerase-independent regulation of ATR by human telomerase RNAMartijn Kedde, Carlos le Sage, Anja Duursma, et al.
Blood Advances|January 4, 2018
Patient-derived antibody recognizes a unique CD43 epitope expressed on all AML and has antileukemia activity in miceMarijn A Gillissen, Greta de Jong, Martijn Kedde, et al.
Cell|December 25, 2007
RNA-binding protein Dnd1 inhibits microRNA access to target mRNAMartijn Kedde, Markus J Strasser, Bijan Boldajipour, et al.
Blood|October 25, 2017
AML-specific cytotoxic antibodies in patients with durable graft-versus-leukemia responsesMarijn A Gillissen, Martijn Kedde, Greta de Jong, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Cell Cycle (Georgetown, Tex.)|April 17, 2008
Interplay between microRNAs and RNA-binding proteins determines developmental processesMartijn Kedde, Reuven Agami
Nature Reviews. Cancer|August 9, 2011
MicroRNA regulation by RNA-binding proteins and its implications for cancerMarieke van Kouwenhove, Martijn Kedde, Reuven Agami
RNA (New York, N.Y.)|March 28, 2008
miR-148 targets human DNMT3b protein coding regionAnja M Duursma, Martijn Kedde, Mariette Schrier, et al.
Nature Cell Biology|September 7, 2010
A Pumilio-induced RNA structure switch in p27-3' UTR controls miR-221 and miR-222 accessibilityMartijn Kedde, Marieke van Kouwenhove, Wilbert Zwart, et al.
The Journal of Biological Chemistry|November 14, 2006
Telomerase-independent regulation of ATR by human telomerase RNAMartijn Kedde, Carlos le Sage, Anja Duursma, et al.
Blood Advances|January 4, 2018
Patient-derived antibody recognizes a unique CD43 epitope expressed on all AML and has antileukemia activity in miceMarijn A Gillissen, Greta de Jong, Martijn Kedde, et al.
Cell|December 25, 2007
RNA-binding protein Dnd1 inhibits microRNA access to target mRNAMartijn Kedde, Markus J Strasser, Bijan Boldajipour, et al.
Blood|October 25, 2017
AML-specific cytotoxic antibodies in patients with durable graft-versus-leukemia responsesMarijn A Gillissen, Martijn Kedde, Greta de Jong, et al.
Pageof 1